ConductScience.org, home

Paper42318924

A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shock.

Sulaiman H and 13 others. J Antimicrob Chemother, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shock. Papers, record 42318924. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42318924

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A multicentre evaluation of pharmacokinetic/pharmacodynamic target attainment of piperacillin and tazobactam and the association with clinical outcomes in critically ill patients with sepsis and septic shock.
PubMed
Journal
J Antimicrob Chemother
PubMed
Year
2026
PubMed
Publication types
Journal Article, Multicenter Study
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sulaiman HHelmihttps://orcid.org/0000-0001-7541-6615
2Wölky SASaskia A
3Rozali MAMuhammad Azrai
4Adiraju SKSSantosh K S
5Hasan MSM Shahnazhttps://orcid.org/0000-0002-7493-7416
6Hernandez-Mitre MPMaria Patriciahttps://orcid.org/0000-0003-3565-0292
7Liu XXinhttps://orcid.org/0000-0002-6210-8100
8Mat-Nor MBMohd-Basri
9Mazlan MZMohd Zulfakar
10Salmuna ZNZeti Norfidiyati
11Wallis SCSteven Chttps://orcid.org/0000-0002-2392-9854
12Xie JJiaohttps://orcid.org/0000-0002-7115-829X
13Roberts JAJason A
14Abdul-Aziz MHMohd Hhttps://orcid.org/0000-0002-8889-5579

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PiperacillinMajor topic
Anti-Bacterial AgentsMajor topic
Penicillanic AcidMajor topic
SepsisMajor topic
Shock, SepticMajor topic
Humans
Female
Critical Illness
Middle Aged
Aged
Male
Adult
Prospective Studies
Treatment Outcome
Tazobactam
Aged, 80 and over
Young Adult
Adolescent
Plasma
Piperacillin, Tazobactam Drug Combination

Source PubMed

Download CSV of topics

Grants9

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
APP2009736Australian National Health and Medical Research CouncilPubMed
Advancing Queensland Clinical FellowshipPubMed
PV023-2017University Malaya PrivatePubMed
82003860National Natural Science Foundation of ChinaPubMed
2024SF-YBXM-277Key Research and Development Program of ShaanxiPubMed
IIT Clinical Research FundPubMed
M097Hospital of Xi'an Jiaotong UniversityPubMed
FRGS16-048-0547Ministry of Higher Education of MalaysiaPubMed
APP2007007Australian National Health and Medical Research Council Centre of Research ExcellencePubMed

Source PubMed

Download CSV of grants

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139699210Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/39699210PubMed
229080413A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent.J Pharm Biomed Anal2018https://conductscience.org/library/papers/29080413PubMed
332150603
The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study.
Clin Infect Dis2021https://conductscience.org/library/papers/32150603PubMed
436272277
The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial.
J Crit Care2023https://conductscience.org/library/papers/36272277PubMed
539628093Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients.J Clin Pharmacol2025https://conductscience.org/library/papers/39628093PubMed
69455502Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.Clin Infect Dis1998https://conductscience.org/library/papers/9455502PubMed
736633812Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult Lifespan.Clin Pharmacokinet2023https://conductscience.org/library/papers/36633812PubMed
837615245
International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists.
Pharmacotherapy2023https://conductscience.org/library/papers/37615245PubMed
924080664Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?Antimicrob Agents Chemother2013https://conductscience.org/library/papers/24080664PubMed
1026754759
Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
Intensive Care Med2016https://conductscience.org/library/papers/26754759PubMed
1129091190Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.J Antimicrob Chemother2017https://conductscience.org/library/papers/29091190PubMed
1226787689Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.Antimicrob Agents Chemother2016https://conductscience.org/library/papers/26787689PubMed
1326903338The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA2016https://conductscience.org/library/papers/26903338PubMed
1433558347
Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).
BMJ Open2021https://conductscience.org/library/papers/33558347PubMed
1525823963Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.J Clin Pharmacol2015https://conductscience.org/library/papers/25823963PubMed
1624429437DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?Clin Infect Dis2014https://conductscience.org/library/papers/24429437PubMed
1737384803Bacterial Resistance in Hospital-Acquired Infections Acquired in the Intensive Care Unit: A Systematic Review.Acta Medica (Hradec Kralove)2023https://conductscience.org/library/papers/37384803PubMed
1825894901Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.Eur J Drug Metab Pharmacokinet2016https://conductscience.org/library/papers/25894901PubMed
1932383061Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.Intensive Care Med2020https://conductscience.org/library/papers/32383061PubMed
2040239817Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: A randomized controlled trial.J Infect2025https://conductscience.org/library/papers/40239817PubMed

See all 34 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42318924

GET https://conductscience.org/api/papers/v1/42318924/references?page=2